NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NURO stock opened at $4.51 on Thursday. The firm has a market capitalization of $9.26 million, a price-to-earnings ratio of -0.98 and a beta of 2.15. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73. The company has a 50 day moving average price of $4.30 and a 200 day moving average price of $4.12.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC acquired a new position in NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned 0.57% of NeuroMetrix at the end of the most recent reporting period. 19.40% of the stock is owned by institutional investors and hedge funds.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.